[Metabolic effects of a fixed combination (betablocker plus saluretic) in long-term treatment of arterial hypertension (author's transl)].
In 23 patients with essential hypertension of stage I and II according to the WHO, the effects of a fixed combination of a beta-receptor-blocker plus saluretic composed of 20 mg of metipranolol (Disorat 20) and 2.5 mg of butizid (Saltucin) = Torrat on blood pressure and important metabolic parameters (glucose, glucose tolerance, cholesterol, triglyceride, uric acid, plasma potassium and whole body potassium) were tested over a 6-month treatment period.


RESULTS
blood pressure and pulse rate were significantly reduced; bradycardia (pulse rate less than 60/min) was not observed. The metabolic parameters showed no significant changes during the 6-month treatment period. In no case did the therapy have to be discontinued because of undesirable effects. The investigations show that the combination has a good antihypertensive effect with few side-effects and that it has no influence on important metabolic parameters during long-term therapy.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy*; D008134:Long-Term Care; D008297:Male; D014290:Metipranolol / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D011188:Potassium / Q000378:metabolism; D011412:Propanolamines / Q000627:therapeutic use*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood
D001786:Blood Glucose; D004338:Drug Combinations; D011412:Propanolamines; D014280:Triglycerides; D006852:Hydrochlorothiazide; D014527:Uric Acid; C018401:Torrat; D002784:Cholesterol; D011188:Potassium; D014290:Metipranolol
Antihypertensive Langzeitbehandlung mit Torrat. Metabolische Wirkungen einer festen Beta-Rezeptorenblocker-Saluretikum-Kombination.